AZNH vs VXUS
AstraZeneca PLC ADRhedged vs Vanguard Total International Stock ETF
Which is better, AZNH or VXUS?
Multi Alternative against Large Cap Blend.
VXUS has a lower expense ratio. AZNH led over 1Y, VXUS over the full window.
MarketXLS is not an investment adviser. This comparison is generated automatically from market data and is for information only. A Best mark means the better reading on that one measure, not a recommendation to buy.
Side-by-Side Comparison
| Metric | AZNH | VXUS |
|---|---|---|
| Expense Ratio | 0.19% | 0.05%Best |
| AUM | $1M | $158.1B |
| Dividend Yield | 1.07% | 2.51% |
| Holdings | 2 | 8,747 |
| Volatility (annualized) | 21.7% | 8.1%Best |
| Max Drawdown | -17.4% | -13.6%Best |
| $10,000 over 1.3 years | $11,527 | $12,954Best |
| Fund Family | ADRH | Vanguard (US) |
| Category | Alternative | Equity |
| Style | Multi Alternative | Large Cap Blend |
| Inception | Oct 1, 2024 | Jan 26, 2011 |
Not shown on this pair: YTD Return, 1Y Return, 3Y Return (annualized), 5Y Return (annualized), Top 10 Weight.
The two price series end 224 days apart, so a return over any period would be measuring two different stretches of market. Those rows are withheld. AZNH has data through Jan 30, 2026 and VXUS through Sep 11, 2026.
Volatility and max drawdown, and the $10,000 over 1.3 years row, are measured over the window both funds cover: Oct 7, 2024 to Jan 30, 2026 (1.3 years).
Risk: Volatility and Drawdowns
AZNH has been the more volatile fund, with annualized monthly volatility of 21.7% compared with 8.1% for VXUS. Lower volatility generally means a smoother ride, though it often comes with lower long-run returns.
The deepest peak-to-trough decline in our data was -17.4% for AZNH and -13.6% for VXUS. Drawdown depth is what each fund did in the worst stretch of the window measured above.
The two funds' monthly returns correlate at -0.13. They move largely independently of each other.
Fees and Cost Over Time
AZNH charges 0.19% per year while VXUS charges 0.05%. On a $10,000 position that is $19 vs $5 annually, a gap of $14 per year that compounds over a long holding period. On income, AZNH currently yields 1.07% against 2.51% for VXUS.
Holdings Overlap
We hold position weights for 1 holding in AZNH and 8,091 in VXUS, totalling 96.3% and 87.7% of the two funds. Neither is a share of a fund we can divide by, so no overlap percentage is shown here. Within what we can see, 1 positions appear in both.
The two holdings books were reported 242 days apart, AZNH as of Oct 31, 2025 and VXUS as of Jun 30, 2026, so some of the difference between them is the time between the two reports rather than the funds.
1 positions in common, counted across the 1 positions we hold weights for in AZNH and 8,091 in VXUS, against full books of 2 and 8,747.
Top Shared Holdings
| Stock | Weight in AZNH | Weight in VXUS | Difference |
|---|---|---|---|
| AZN:LNDeveloped Markets Astrazeneca Plc Sponsored Adr | 96.33% | 0.62% | 95.71% |
You are not choosing between two funds in isolation.
Whichever of AZNH and VXUS you pick has to sit alongside everything else you own. Add the rest and see what the combination actually holds.
Free for up to 10 holdings. No account needed.
Frequently Asked Questions
Which is cheaper, AZNH or VXUS?
AZNH has an expense ratio of 0.19% while VXUS charges 0.05%. VXUS is the cheaper option, by $14 a year on a $10,000 investment.
Which is riskier, AZNH or VXUS?
AZNH has been the more volatile fund at 21.7% annualized versus 8.1% for VXUS. Worst drawdown: AZNH -17.4% vs VXUS -13.6%.
Should I hold both AZNH and VXUS?
AZNH and VXUS have a monthly-return correlation of -0.13, so their returns are far enough apart for the mix to behave differently from either one alone. This is information, not a recommendation.
Which pays a higher dividend, AZNH or VXUS?
AZNH yields 1.07% while VXUS yields 2.51%, so VXUS currently pays the higher dividend yield.
Is VXUS better than AZNH?
VXUS has a lower expense ratio. AZNH led over 1Y, VXUS over the full window. Which one suits a particular account depends on what it is for. This is information, not a recommendation.